DiaMedica Announces Resignation of Board Member

DiaMedica (TSX VENTURE:DMA) announces today that David Allan has resigned from
the Company's board of directors, effective February 22, 2013.


"On behalf of our board of directors, I thank David for his valuable service and
contributions and wish him well in future endeavors," stated Rick Pauls,
Chairman & CEO of DiaMedica.


About DiaMedica 

DiaMedica Inc. (TSX VENTURE:DMA) is a biotechnology company developing
first-in-class treatments for the treatment of diabetes. DiaMedica's lead
compound, DM-199, is a recombinant human protein for the treatment of both Type
1 and Type 2 diabetes and their complications. The Company is also developing
the first therapeutic GPCR agonist monoclonal antibody, DM-204, for the
treatment of Type 2 diabetes and cardiovascular disease. DiaMedica's shares
trade on the Toronto Stock Exchange Venture (TSX VENTURE:DMA). For more
information please visit www.diamedica.com.


FORWARD-LOOKING STATEMENTS 

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Corporation's filings with Canadian securities regulatory authorities. Should
one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Corporation undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica Inc.
Rick Pauls
Chairman & CEO
763-710-4455
[e-mail]
www.diamedica.com